Novartis and the Bill and Melinda Gates Foundation are collaborating to develop a single-shot gene therapy that would cure sickle cell disease (SCD) without the need to engineer cells outside the body. The partnership aligns with Novartis’ efforts to better treat SCD, and the Gates Foundation‘s goal of expanding access to quality healthcare in resource-poor areas. “Existing gene therapy approaches to sickle cell disease are difficult to deliver at scale and there are obstacles to…

You must be logged in to read/download the full post.